NewsApp (Free)

Read news as it happens
Download NewsApp

Available on  

Rediff News  All News  » Business » Piramal Group's PE to raise $185 mn in new fund

Piramal Group's PE to raise $185 mn in new fund

Last updated on: December 7, 2012 11:18 IST

Piramal Group's PE to raise $185 mn in new fund

Indulal PM

IndiaVenture Advisors, a private equity fund owned by Indian drugmaker Piramal Enterprises, is planning to raise up to 10 billion rupees ($185 million) for a new fund that will invest in healthcare and education, its chairman said.

Investors have stepped up ploughing money into the healthcare sector in India, home to more than 1.2 billion people, betting on steadier returns than in other businesses that have been hit by an economic slowdown.

"It's a defensive sector and is recession-proof," IndiaVenture chairman A K Purwar told Reuters. "On top of that, we have our parent group's strength to leverage and do better value addition."

IndiaVenture currently manages about Rs 3.7 billion.

Private equity investments in Indian healthcare have nearly quadrupled to $520.36 million so far this year from $137.41 million in the same period a year ago, according to Thomson Reuters data.

In comparison, private equity investments across all sectors in India have fallen 17.5 per cent to $3.26 billion from $3.95 billion during the same period last year, the data showed.

"We are about to start formal marketing of the fund," said Purwar, a former chairman of top lender State Bank of India .

The bulk of the fund would be raised from India, while global investors would be tapped for about 20 per cent, he said.

Piramal Enterprises, controlled by billionaire Ajay Piramal, is one of India's leading healthcare firms. It sold its India formulations business to U.S.-based Abbott Laboratories for $3.7 billion in 2010.

($1 = 54.0950 Indian rupees)

Image: Ajay Piramal, chairman of Piramal group.
Photographs: Arko Datta/Reuters

© Copyright 2018 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.